ROS, Cell Senescence, and Novel Molecular Mechanisms in Aging and Age-Related Diseases by Davalli, Pierpaola et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ROS, Cell Senescence, and Novel Molecular Mechanisms in
Aging and Age-Related Diseases
Citation for published version:
Davalli, P, Mitic, T, Caporali, A, Lauriola, A & D'Arca, D 2016, 'ROS, Cell Senescence, and Novel Molecular
Mechanisms in Aging and Age-Related Diseases' Oxidative Medicine and Cellular Longevity, vol. 2016, pp.
3565127. DOI: 10.1155/2016/3565127
Digital Object Identifier (DOI):
10.1155/2016/3565127
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Oxidative Medicine and Cellular Longevity
Publisher Rights Statement:
Copyright © 2016 Pierpaola Davalli et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Review Article
ROS, Cell Senescence, and Novel Molecular Mechanisms in
Aging and Age-Related Diseases
Pierpaola Davalli,1 Tijana Mitic,2 Andrea Caporali,3
Angela Lauriola,1 and Domenico D’Arca1,4
1Department of Biomedical, Metabolic and Neural Sciences, University of Modena & Reggio Emilia, 41125 Modena, Italy
2Bristol Heart Institute, University of Bristol, Bristol BS2 8HW, UK
3University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, 47 Little France Crescent,
Edinburgh EH16-4TJ, UK
4Istituto Nazionale di Biostrutture e Biosistemi, 00136 Roma, Italy
Correspondence should be addressed to Domenico D’Arca; domenico.darca@unimore.it
Received 16 December 2015; Revised 2 April 2016; Accepted 6 April 2016
Academic Editor: Michael Courtney
Copyright © 2016 Pierpaola Davalli et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The aging process worsens the human body functions at multiple levels, thus causing its gradual decrease to resist stress, damage,
and disease. Besides changes in gene expression and metabolic control, the aging rate has been associated with the production
of high levels of Reactive Oxygen Species (ROS) and/or Reactive Nitrosative Species (RNS). Specific increases of ROS level have
been demonstrated as potentially critical for induction and maintenance of cell senescence process. Causal connection between
ROS, aging, age-related pathologies, and cell senescence is studied intensely. Senescent cells have been proposed as a target for
interventions to delay the aging and its related diseases or to improve the diseases treatment. Therapeutic interventions towards
senescent cells might allow restoring the health and curing the diseases that share basal processes, rather than curing each disease in
separate and symptomatic way. Here, we review observations on ROS ability of inducing cell senescence through novel mechanisms
that underpin aging processes. Particular emphasis is addressed to the novel mechanisms of ROS involvement in epigenetic
regulation of cell senescence and aging, with the aim to individuate specific pathways, which might promote healthy lifespan and
improve aging.
1. Introduction
The reduced rate of birth and mortality is the motive of the
older population growth in western industrialized countries,
where advanced age remains the fundamental risk factor for
most chronic diseases and functional deficits. As an example,
it is estimated that the individuals of age 65 and above in the
USA will reach 20% by 2030, while they constituted 12.4% in
2004 [1]. Human aging is developed from such an accumu-
lation of physical, environmental, and social factors that the
definition of themolecularmechanisms that trigger the aging
means a difficult task. Some theories associate various factors
with aging rate, as changes of metabolic control [2] and
gene expression patterns [3] and production of high levels of
Reactive Oxygen Species (ROS) [4]. Low ROS level has been,
instead, associated with lengthening of organismal lifespan
[5]. Current studies aim at deepening how cell senescence
process, so far experimented in vitro, may be extended to in
vivo studies. Increasing evidence for causal role of cell senes-
cence has been demonstrated in age-related dysfunctions and
pathologies [6]. Senescent cells proliferate in aging, as a stress
response primed by a number of “countingmechanisms,” like
telomeres shortening, DNA damage accumulation, abnormal
oncogenes activities, metabolic alterations, and excessive
ROS generation [7]. These mechanisms cause cell proliferat-
ing arrest and generate features, as constitutive production of
high ROS levels, critical for the senescent phenotype mainte-
nance. Despite increasing modestly, as a number, the senes-
cent cells are implicated in age-related diseases promotion,
through the restriction of the regenerative pool of the tissue
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stem cells [8]. Some observations indicate that senescent cells
do not necessarily induce mechanisms that promote aging
and can be efficiently removed from the human body [9].The
general consensus on cellular damage accumulation, as aging
initial event, suggests that cell senescence process is a major
question regarding biological and clinical aging aspects [10].
Here, we review evidences on novel molecular mech-
anisms of the “ROS signaling” during aging and related
pathologies, because they suggest a way of promoting healthy
lifespan and improve human aging.
2. ROS Physioma Homeostasis
The ROS physioma is a family of highly reactive molecules
which includes free oxygen radicals, like superoxide anion
(O
2
∙−), hydroxyl radical (OH∙), and nonradical oxygen
derivatives, like the stable hydrogen peroxide (H
2
O
2
). The
superoxide radicals react to form other ROS, namely, hydro-
gen peroxides and hydroxyl radicals, and interconvert with
reactive nitrogen species (RNS), which generate effects simi-
lar to ROS [11]. The inefficient electron transfer in mitochon-
drial respiratory chain is believed to be a main ROS source,
among diverse possible enzymatic and nonenzymatic sources
[12]. Increased expression of catalase and peroxiredoxin-
1 molecules are considered as OS markers. The family
comprises seven transmembrane members, namely, Nox1–
5 [13–15] and Duox1-2 [16]. ROS are generated by oxygen
metabolism (i.e., cellular respiration) in all the cells that
utilize oxygen, as inevitable consequence of aerobic life,
and may derive from exogenous metals, recycling of redox
compounds, radiation, chemotherapeutic agents, carcino-
gens (estrogenic molecules), and other dietary and environ-
mental means. Generally, the ROS increasing levels cause
nonlinear cellular responses [17]. A fine balance between
oxidant-antioxidant mechanisms leads to continuous mod-
ulation of ROS production, location, and inactivation, in
both physiological and pathological conditions. Endogenous
antioxidants, like the enzymes of catalase family, glutathione
group, thioredoxin-related group, and superoxide dismutase
[18], together with exogenous antioxidant as reduced glu-
tathione [19], carotenoids, and vitamins C and E, constitute
the indispensable ROS detoxifying system. Nevertheless,
imbalance of redox homeostasis may occur, usually in favor
of oxidants, so that ROS shift from physiological to poten-
tially harmful levels, named oxidative and nitrosative stress
(OS/NS). Increased expression of catalase and peroxiredoxin
1 molecules are considered as OS markers [20–22].
2.1. ROSMeasurement Techniques. ROS are so highly variable
and freely diffusible molecules that the detection of ROS and
antioxidants, to obtain a picture of the cellular redox status,
still represents a challenge.We stress some specific points and
sensitive methods that are subjected to continuous improve-
ment. Probes and antibodies have been developed to recog-
nize oxidative damage by ROS/RNS [23–25]. The tools allow
revealing antioxidant enzymes [26] and a variety of oxidative
products, as lipid peroxidation products, protein carbonyls
[27], oxidized DNA products [28], and nitrotyrosine [29].
Combinations of diverse approaches will prove essential for
understanding ROS involvement in aging and age-related
diseases [30]. An innovative method simultaneously assesses
glutathione, hydrogen peroxide, and superoxide levels in
a single cell, together with cell viability alterations, thus
allowing for defining both oxidant-antioxidant balance and
cell death, after the administration of a specific stimulus [31].
A wide range of pathways and molecular mechanisms that
involve ROS suggests determining the redox state of thiols in
ROS targets, which compose the “cellular oxidative interface”
[32, 33]. ROS oxidize specific protein residues of cysteine into
sulfenic acid, reversibly. This molecule functions as OS/NS
sensor within enzymes and transcriptional regulatory factors
and may allow priming the routes of the versatile ROS action
[34–36].
2.2. ROS Functions. The increasing comprehension of mech-
anisms, underlying the oxidant milieu of the cell, shows
ROS as signaling molecules, besides metabolic byproducts.
They act in a myriad of pathways and networks, mediated
by hormones, which ranges from protein phosphorylation
to transport systems, for example. ROS do not influence
single steps of multistep processes; rather, they influence
all the steps at the same time, by reacting with several
compounds and taking part in several redox reactions.
Depending on ROS concentration, molecular species, and
subcellular localization, cell components and signaling path-
ways are affected positively or negatively. ROS levels are
believed to be a “redox biology” that regulates physiological
functions, including signal transduction, gene expression,
and proliferation. “Redox biology,” rather than OS, has been
proposed to underlie both physiological and pathological
events [37]. Data in the literature on slow and constant
ROS increases have to be integrated with data on fast and
stepwise ROS increases, typical of signaling events, which
deliver messages among cellular compartments. Questions
related to ROS dynamics and specificity, as the effects of their
waves of concentration on networks with other signaling
pathways, are investigated in single cells and across different
cells. Proteins are the major target of ROS/RNS signaling
and undergo reversible or irreversible modifications of their
functions, which result in cell death, growth arrest, and
transformation. The modulation of the reversible oxida-
tion of redox-sensitive proteins plays basic roles in sens-
ing and transducing the oxygen signal. Receptor-dependent
or nondependent tyrosine kinases, AMP-activated protein
kinases, adaptor protein p66SHC, and transcription factors
as FOXO (forkhead homeobox type O), Nrf2 (nuclear fac-
tor E2-related factor 2), p53 (tumor suppressor 53), NF-
𝜅B (nuclear factor kappa B), AP-1 (activator protein-1),
HIF-1a (hypoxia inducible factor-1a), PPAR𝛾 (peroxisome
proliferator-activated receptor gamma), and 𝛽-catenin/Wnt
signaling are listed in Table 1 [38–81]. ROS mediate in vitro
response towards intra- and extracellular conditions, such as
growth factors, cytokines, nutrients deprivation, andhypoxia,
which regulate cell proliferation, differentiation, and apopto-
sis, besides being important cancer hallmarks [82]. Intrinsic
and extrinsic factors control ROS regulation on cellular self-
renewal, quiescence, senescence, and apoptosis, during the
in vivo tissues homeostasis and repair [83] and in ROS
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Table 1: Selected ROS sensitive proteins that are involved in cell signaling transduction mechanism. Indicative examples of possible effects
and processes they promote after being directly and/or indirectly modified by ROS (the references are indicated inside the square brackets).
ROS sensitive proteins:
oxidative interface
(1) Effects of ROS sensitive proteins after being
redox modified
(2) Physiopathological processes in which ROS
sensitive proteins are involved
Protein kinases
Receptor/nonreceptor tyrosine
kinases
(Src, TRK, AKT, c-Abl, MAPK,
CaMKII, PKG, ATM, and Ask1)
(i) Interactions between kinases pathways [38, 39]
(ii) Signal of ROS production feedback [40]
Control of cell cycle progression [56]
Mitosis for anchorage-dependent cells [57]
Cellular homeostasis [43, 57]
AMP-activated protein kinases
(AMPK) (i) Regulation of cell ROS/redox balance [41, 42]
Myocyte adaptation to energy requirement [42]
Adipocyte differentiation [58]
Lipid metabolism (“fatty liver”) [59]
Hyperglycemic damage [60]
Cell fate (autophagy and apoptosis) [61]
Adaptor proteins
p66Shc (i) Signaling start in the aging process [43]
Apoptosis [43]. Prolonged life span [43, 62]
Cardiovascular diseases and obesity [63]
Diabetic endothelial dysfunction [64]
Nuclear receptors
PPAR𝛾
(i) Redox sensor function [43]
(ii) Regulation of genes that modulate ROS
increases [44]
Neurodegenerative diseases [65, 66]
Lipid dysfunction (fatty liver) [59]
Membrane receptors
Elements in Notch1 pathway (i) Notch signaling modulation in associationwith Wnt/beta-catenin signal [45]
Cell fate control in vascular development [45]
Biological clocks in embryonic development [67]
Transcription factor
p53 Modulation of cell redox balance(prooxidant/antioxidant effects) [46–48]
Cell fate signaling [68]
Autophagy and apoptosis [61, 69]
Nrf2 Cell adaptation to ROS resistance [49, 50]
Apoptosis [70]
Neurodegenerative diseases [71]
Cardiovascular diseases [72]
FOXO3A Cell coordination in response to OS [51]
Metabolic adaptation to low nutrient intake [73]
Cancer development [73]
Diabetes [74]
Atherosclerotic cardiovascular disease [75]
Components in 𝛽-catenin/Wnt
pathway
Regulation of Wnt signaling via nucleoredoxin
[76]
Early embryonic development [76]
Vascular development [45]
HIF-1a Cell adaption to oxygen tension modifications[52]
Cell proliferation; angiogenesis [77]
Cell transformation [78, 79]
Components in JAK–STAT
pathway
(i) Cell adaption to OS [53]
(ii) Mediation of ROS mitogenic effect [53]
Stress response gene expression [51]
Systemic/pulmonary hypertension [80]
NF-𝜅B Regulation of redox-sensitive gene expression[54, 55]
Rheumatoid arthritis, dyslipidemia,
atherosclerosis, and insulin resistance [81]
induction of stem cells proliferation and differentiation. ROS
act as a rheostat, which senses and translates environmental
cues in stem cells response, thus balancing cellular output
(function) with cellular input (nutrients, cytokines). The
stem cells may undergo exhaustion depending on ROS levels
[84]. Mitochondrial ROS may activate an adaptive response
(mitohormesis), which, as defensive mechanism, promotes
health to extend the lifespan through diseases prevention
and delay [5, 85]. ROS is integral in the development of
physiopathologic events like mitochondrial death signaling
[86] and autophagy [87], besides inflammation and infection
[55, 88], in which they impart immunological changes. High
ROS levels are generated by professional cells (lymphocytes,
granulocytes, and phagocytes) in defense against microbes
[89, 90]. Differently, any event which contributes to chronic
OS or NS, through its increased generation or defective
detoxification, dysregulates signaling networks, alters lipids
and protein and nucleic acids, and activates mechanisms to
face the changes. ROS overproduction hampers damaged
nuclear and mitochondrial DNA repair, at multiple steps,
contributing to cell genomic instability [91]. ROS are rec-
ognized as key modulators in processes that accumulate
oxidized molecules chronically, as diabetes, cardiovascular
diseases, atherosclerosis, hypertension, ischemia, reperfusion
injury, neurodegeneration, and rheumatoid arthritis [17].
Also, ROS participate in cancer development through their
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effects on cellular proliferation, mutagenesis, and apoptosis
inhibition [56]. The cross talk between ROS, p53, and NF-𝜅B
plays crucial roles in tumorigenesis. OS is allied with energy
metabolism to stimulate the growth of cells transformed by
oncogenes or tumor suppressors [92–94]. The deregulated
ROS productions in cancer cells and the consequent consti-
tutive OS may cause the cellular invasive phenotype [57].
Although ROS functions remain difficult to investigate,
multiple pharmacological investigations are in progress to
maintain ROS homeostasis through both OS decrease and
antioxidant defense increase [95, 96].
3. ROS in Aging and Age-Related Diseases
Poor knowledge of basic processes in aging interferes with
interventions to prevent or delay age-related pathologies,
like diabetes, cardiovascular disorders, neurodegenerative
disorders, and cancer, which, consequently, impact human
independence, general wellbeing, and morbidity [97–99].
Recently, interest has been focused on stem cells, because
their decline impairs tissues homeostasis maintenance, lead-
ing to the organism weakening and the age-related diseases
[84]. Agingmechanisms have been collected into two classes.
The first class presents aging as genetically programmed
by developmental processes, like the cell senescence, the
neuroendocrine alterations, and the immunological alter-
ations. The second class presents aging caused by random
damage, that is, accumulation of somatic mutations and OS.
The separation between the classes is no longer considered
clear, because pathways involved in aging often share features
with specific diseases [100]. The genetic heredity contributes
no more than 3% to aging, while epigenetic processes and
posttranslational processes imprint a significantly different
aging rate among diverse populations, as well as among
diverse anatomical sites of a single organism. In the onset
of aging, telomere erosion, OS, and cell senescence are
crucial events that originate from the disorganized homeosta-
sis of cell metabolism. For example, mitochondria-nucleus
interplay [101] and alterations of mitochondrial homeostasis
drive age-dependent modifications [102, 103]. Ineffective
ROS control on mitochondrial supercomplexes causes ROS
signaling alteration, thus mediating cell stress responses
towards age-dependent damage [104]. A progressive ROS
scavengers decrease shifts aged cells towards a prooxidant
status [105, 106]. In parallel, all the suggested methods to
prolong lifespan, as caloric restriction and increased activity
of SIRT1, share the OS reduction effect [107]. It is known
that chronic muscular exercise protects older persons from
damage caused by OS and reinforces their defenses against it.
On the other hand, acute exercise increases ROS production
and damage from ROS [108]. High levels of mitochondrial
ROS contribute to aging of genetically modified animals, in
a mechanistic way. Superoxide dismutase-deficient animals,
SOD1- [109] and SOD3-deficient animals [110], and p66SHC-
deficient animals showmitochondrial dysfunctions that gen-
erate oxidative damage and related phenotypes, resembling
premature aging features. Similarly, mice that overexpress
mitochondrial catalase counteract oxidative damage and live
longer. The incidence of age-related diseases and pathologies
in animal models, after they have been submitted to disparate
patterns, suggests that OS influences old age aspects signifi-
cantly [111].The observations have been extended to humans,
even if rate and distribution of mitochondrial mutations may
deviate from animals.The conclusions regarding OS effect on
aging in animals from mitochondrial genetic manipulations
are still conflicting. SOD+/− mice have reduced ROS detox-
ifying ability and high ROS level, while they exhibit a quite
normal lifespan. OS effect on worms’ lifespan depends on
where ROS are produced: high mitochondrial or cytoplasmic
levels are associated with increased and decreased lifespan,
respectively [109, 112]. It remains to define whether models’
longevity is entirely associated with response to OS, because
their lifespan is not affected by modulation of the antioxidant
defense. The complex genetic manipulation of the models
might weaken their support to the “OS theory of aging.”
Interventions to ROS lowering, by both scavenging free
radicals and enhancing antioxidant defenses, are widely pro-
posed as an antiaging strategy. However, positive association
between supplementation with pharmacological or natural
compounds and health beneficial effects has not been evi-
denced. Some antioxidants may be eventually useless or even
harmful [113, 114]. Moreover, a number of ROS-independent
mitochondrial dysfunctions appear so involved in aging that
doubts arise that OS is the most concrete contributor to fuel
aging [115]. Based on the consideration that mitochondrial
DNA (mtDNA) is a precise marker to detect total mitochon-
drial OS, methods have been developed to measure mtDNA
replication defects and the oxidative damage level, simulta-
neously. The errors in mtDNA replication and repair, which
accumulate through clonal expansion in advanced age, result
in amajor source ofmtDNAmutations, rather than the errors
acquired through ROS-dependent vicious cycles [116]. Sum-
marizing, ROS are involved in elderly lesions that concern (i)
DNA insufficiency, which is partly responsible for premature
aging and apoptosis [117]; (ii) RNA involvement in the onset
of chronic-degenerative diseases [118]; (iii) nuclear lamins
that participate in cell proliferation and longevity [119]. The
variations of speed and quality in the aging of each organism
may reflect the peculiar alterations that have been accumu-
lated in DNA, proteins, and lipids [120], following the organ-
ism exposition to chronic stressors. Low ROS levels improve
the defense mechanisms by inducing adaptive responses,
which contributes to stress resistance and longevity, while
high ROS levels induce insufficient adaptive responses, which
may contribute to aging onset and progression [121].
In conclusion, accumulated mutations, decreased mito-
chondrial energy metabolism, and increased OS may signifi-
cantly contribute to the human aging and the related diseases.
4. ROS-Dependent Epigenetic Modifications
Intra- and extracellular environments change hereditary cha-
racters at the epigenetic level, without altering genes sequence
[122].The interplay between modified histones, DNAmethy-
lation, regulator noncoding RNAs, and other reversible pro-
cesses constitutes the epigenetic machinery that regulates
genes transcription and expression [123]. The epigenetic
modulation provides the essential and flexible interface
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between organism and environment, which is essential for all
the cell functions.The extent to which epigenome has shaped,
and might shape, human populations over generations is
investigated by an International Human Epigenome Con-
sortium (http://www.ihec-epigenomes.org/). Both long- and
short-acting stimuli lead to epigenetic effects that result in
13 being long-term (heritable) or short-term (nonheritable),
respectively. These features suggest epigenetic modifications
as more attractive target for therapeutic interventions in
humans than genetic modification, throughout the entire
life [124]. ROS operate modifications on histone and DNA,
by acting in interconnected epigenetic phases, during mito-
chondrial and nuclear DNA regulation [125, 126]. A clin-
ical example of ROS-dependent epigenetic modifications
is demonstrated in “nonalcoholic fatty liver” disease. The
pathology represents themost common cause of chronic liver
disease in western countries and affects one-third of the pop-
ulation. Altered redox mechanisms mediate the link between
increased accumulation of triglycerides in hepatocytes and
epigeneticmodifications that are recognized as crucial factors
in the pathophysiology of this disease [127]. About the basic
mechanisms of ROS action, Afanas’ev proposes that ROS
might cause epigenetic activation and repression, by acting
like nucleophilic compounds, which accelerate and decelerate
hydrolysis and esterification reactions. The hypothesis sug-
gests a ROS role different from free radicals, because the last
molecules cause an irreversible damage of the compounds
with which they react [128].
4.1. ROS-Induced DNA Methylation. Usually, condensed
chromatin structure (heterochromatin) is associated with
genes repression by hypomethylation processes, while open
chromatin (eu-chromatin) is associated with genes activation
by acetylation processes [129]. The epigenetic marking mod-
ulates the genes expression by altering the electrostatic nature
and the protein binding affinity of chromatin. DNAmethyla-
tion causes gene silencing through inhibiting the transcrip-
tional activators access to the target binding sites, or through
activating themethyl-binding protein domains.The last func-
tion interacts with histone deacetylases and promotes chro-
matin condensation into transcriptionally repressive confor-
mations. Hypo- and hypermethylation stages occur consec-
utively, indicating how DNA methylation and the correlate
mechanisms of DNA binding are complex. ROS-dependent
modifications are related to DNA methylation and demethy-
lation, directly or indirectly. The NF-𝜅B binding to DNA,
which is methylation dependent, results in being altered
in SOD (Cu/Zn)-deficient mice. The observation associates
ROS-dependent modifications with altered methylation pro-
cesses, although indirectly, and suggests that modifications
linked to altered redoxmechanismsmay fit into cell signaling
pathways [130]. Also, the oxidation of deoxy-guanine of CpG
nucleotides to 8-hydroxy-2󸀠-deoxyguanosine (8-OHdG) is
believed to be a surrogate marker of oxidative damage, in
various human diseases [131]. The 8-OHdG adducts interfere
withDNA restriction nucleases andDNAmethyl transferases
(DNMT), thus altering transcription factors binding to DNA
and causing general DNA hypomethylation. In vitro [132]
and in vivo [133] studies demonstrate that ROS induce
general genome hypomethylation and specific DNA promot-
ers hypomethylation, via the DNMT upregulation and the
DNMT complexes generation.Moreover, recent studies show
that aROS-mediated pathway causes repression of the protein
kinase C epsilon gene, through its promotormethylation.The
events are important in heart hypoxia, in utero, which leads
to heightened heart vulnerability to ischemic injury, later in
people’s life [134].
4.2. ROS and DNA Methylation in Aging and Age-Related
Diseases. Starting from the observation that both defective
genome and DNA repair processes promote phenotypes of
premature aging, the “aging epigenetics” has been developed
as emerging discipline, which concerns genes and processes
impacting aging (Figure 1) [135]. ROS effects on epigenetic
mechanisms have been discussed as cause and consequence
of aging and age-related DNA modifications [128]. Recent
studies demonstrate that global DNA hypomethylation is
deeply included in aging gene expression [136], and, at the
same time, cancer is the age-related disease that shows the
most significant effects of ROS-dependent DNAmethylation
[137]. Tumor progression is induced by general hypomethy-
lation of theDNA and hypermethylation of tumor suppressor
genes that lead to aberrant genes expression [138–140].
Abnormal and selective DNA methylation may constitute
a potential biomarker and a tool to assess therapeutic
treatments at the same time. The data on OS-mediated
alterations in DNA methylation, which have been so far
obtained, motivate chemoprevention trials, to reduce OS in
cancer diseases [141–143]. In human aging, the telomerase
reverse transcriptase (hTERT) controls the mitochondrial
function and the cellular metabolism, besides the telomeres
structure. The enzyme is regulated by DNA methylation.
Various observations demonstrate that hTERT may confer
major sensitivity towards OS [144] and reduce ROS increase
in aging and age-related diseases [145]. Examples of both
ROS levels and DNA methylation, which seems to change
with age, suggest that they are potentially linked [146, 147].
ROS-inducedmethylation at SOD2 gene promoter causes the
decreased expression of the gene, which may be associated
with the disruption of the cardiorespiratory homeostasis, a
typical problem of the old humans. Treatments with DNA
methylation inhibitors, in preclinical studies, can prevent
the hypoxic sensitivity that leads to the respiratory dysfunc-
tion [148]. Also, both ROS-induced 8-OHdG and 5-methyl
cytosine generate abnormal GC regions in the DNA, which
undergo further methylation and oxidation, thus hampering
DNA repair enzymes.These regions have been demonstrated
to hit gene expression and DNA susceptibility to damage in
Alzheimer’s pathology [149].
In complex, ROS are involved in DNAmethylation proc-
esses in different conditions, occurring in the human aging.
The epigenetic machinery operates as OS sensor, which con-
tributes to the OS control and, at the same time, orches-
trates the progressive homeostasis impairment, which shapes
the cardiovascular, respiratory, and nervous systems of old
human beings [146]. The ROS signaling in the DNA methy-
lation during the aging process deserves to be more deeply
studied.
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Activating signals
Cytokines
Growth factor (mitogens, nutrients)
Stress (hypoxia, UV, radiation,
and chemotherapy)
Mitochondria
ROS
Membrane bound
NADPH oxidases
ROS pool
ROS lev
els
+−
Antioxidants and detoxicating enzymes
SOD, catalase, glutathione,
peroxiredoxin,
thioredoxin reductase, and peroxidase
NADPH oxidase
Accelerated
aging
Cell death
Age-related
diseases
ROS sensitive proteins
(oxidative interface)
Damage
Nucleic acids, lipids, and proteins
Epigenetic machinery
DNA methylation, histone modification,
and noncoding RNAs
Figure 1: Schematic representation of ROS signaling in physiological and pathological conditions. Low andmedium ROS levels produced by
mitochondria and NADPH oxidase activate cell ROS sensitive proteins and epigenetic machinery. High ROS level causes nucleic acids, lipid,
and proteins damage possibly involved in accelerated aging, cell death, and age-related diseases.
5. ROS in Cell Senescence
The cell senescence has indicated the irreversible G1 growth
arrest of normal primary cells, which occurs after the cells
have accumulated time-dependent damage, during extensive
culture passages (“replicative senescence”). The cells resist
apoptosis and face malignant progression through cytosta-
sis, thus causally contributing to cell senescence induction
and maintenance. The senescent cells are able to diversify
constantly, like cancer cells, but missing proliferation as a
driver [7, 9]. Large and flat shape, rich cytoplasmic and
vacuolar granularity, high levels of lysosomal 𝛽-galactosidase
activity (SA-𝛽gal), p16, p21, macroH2A, IL-6, phosphory-
lated p38MAPK, and “double-strand breaks” are the most
common senescent cells features in in situ assays [9]. The
exact mechanisms underlying the cell senescence onset and
stabilization are still obscure. OS, mitochondrial deteriora-
tion, DNA damage, oncogenes expression, and loss of tumor
suppressor genes, like PTEN, RB1, NF1, and INPP4, can
induce cell senescence [9]. “Replicative senescence,” which is
provoked by endogenous stimuli, is distinct from “stress-
induced premature senescence,” which is provoked by exoge-
nous stimuli. The two processes share molecular and func-
tional features, although they are dependent, or not, on
telomeres status, respectively. Intrinsic and extrinsic events
can induce either the cell senescence or the apoptosis process,
depending on the level of the impairment of the cell home-
ostasis [150] and the p53 activity [47].Themolecules secreted
by senescent cells (secretoma) cooperate deeply to maintain
the tissues homeostasis, through autocrine and paracrine
activities [151], by acting at multiple levels: epigenome [152],
gene expression, protein processing, and metabolic control
[153]. Moreover, specific mitochondrial pathways contribute
to priming the senescence process, through the alteration of
the mitochondrial redox state [6, 151]. The senescence secre-
toma acts in physiological and pathological events, as tissue
remodeling during embryogenesis, tissue repair in wound
healing, and induction of aging, as well as age-related diseases
of different organisms. The secretoma develops beneficial
effects on carcinogenic DNA lesions of precancerous cells,
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by both preventing their uncontrolled cell proliferation and
reacting with specific anticancer compounds [154]. However,
the secretoma may provide indispensable cytokines for the
cancer cells growth, thus promoting tumorigenesis in definite
conditions, which are partly related to the cellular meta-
bolic state [155]. Cause-effect relationships between cellular
ROS production and cell senescence have been investigated
through diverse pathways that comprise the following.
(i) Mitochondrial DNA (mtDNA) Damage. ROS contribute
to cellular senescence onset and progression by damaging
mtDNA directly or in synergy with modifications of the
telomerase reverse transcriptase (TERT) enzyme and the
p53 and Ras pathways activity [9]. Also, ROS production
by serial signaling through GADD45-MAPK14 (p38MAPK)-
GRB2-TGFBR2-TGFb is both necessary and sufficient for the
stability of growth arrest, during the establishment of the
senescent phenotype [156].
(ii) Signaling Pathways via Ras, p53, p21, and p16. The path-
ways generate ROS, which act as signalingmolecules, without
causing oxidative DNA damage. ROS result as a tightly regu-
lated signaling process for the induction of the cell senescence
[157].
(iii) Autophagy. High ROS levels mediate p53 activation that
induces autophagy inhibition. This event generates mito-
chondrial dysfunction, which in turn generates cell senes-
cence. The autophagy inhibition causes the senescent cells
to aggregate oxidized proteins and protein carbonyls with
products of lipid peroxidation and protein glycation into the
lipofuscin [158].
(iv)miR-210 andmiR-494.The induction of thesemicroRNAs
by ROS generates mitochondrial dysfunction and autophagy
inhibition [159].
The (iii) and (iv) pathways generate vicious loop cycles
in ROS production. Autophagy inhibition causes lipofuscin
accumulation, which activates further autophagy impairment
and ROS production, consequently. All the factors (i), (ii),
(iii), and (iv) may add to DNA damage and dysfunctions of
bothmitochondria and cell metabolism homeostasis [159]. In
vitro and preclinical experiments show that ROS decreasing
interventions influence cell senescence progression, via the
slowdown of telomere shortening and the extension of the
cell lifespan. Replicative telomere exhaustion, DNA damage,
and OS prime the cell senescence by sharing the activation
of the “DNA Damage Response.” ATM or ATR kinases of
these signaling pathways cause p53 stabilization and tran-
scriptional activation of the p53 target, p21 [9]. p53 triggers
cell cycle arrest by upregulating p21, which inhibits the cell
cycle regulator cyclin-dependent kinases Cdk4 and Cdk2
[159]. Whereas high OS levels induce the prosenescence
function of p53, the mild OS levels that are induced by the
physical exercise in humans have a positive effect on cell and
mitochondrial homeostasis. p53 exerts a dual effect on cell
senescence because of its ability to both decrease and increase
the cellular OS level [160]. In parallel to “DNA Damage
Response,” the mitochondrial p38-MAPK replenishes the
short-lived DNA damage foci, via a ROS feedback loop, and
induces the senescent secretoma [161].
The occurrence of the ROS role in cell senescence onset
and maintenance might be relevant for therapeutic interven-
tions, which aim to modulate ROS levels in cancer cells, as
well as in aging processes [156]. Human kidney dysfunctions
exemplify progressive stages of ROS-induced cell senescence.
ROS act like a sensor in regulating the oxygen-dependent
gene expression of the kidney and play a leading role in
the inflammatory processes, to which the organ is especially
sensitive [162]. In conclusion, the ROS signaling has high-
lighted key factors for the cell senescence induction and
maintenance, which are the object of intensive investigations.
5.1. Cell Senescence in Aging and Age-Related Diseases (ROS
Effect). The “replicative cell senescence” is considered an
aging hallmark on the basis of two motives: (1) the senes-
cent cells accumulate in organismal tissues, by rate and
proportion, which parallel the age advancement; (2) the
senescent cells accelerate the age-related decrease of tissue
regeneration, through the depletion of stem and progenitors
cells [8, 97].While the sequence of proliferative arrest (senes-
cence), recruitment of immune phagocytic cells (clearance),
and promotion of tissue renewal (regeneration) results in
being beneficial upon a damaged tissue, for instance, the
sequence is inefficiently completed in aging tissues, causing
senescent cells to undergo chronic accumulation [163]. Also,
a delicate balance exists between cell senescence positive
effects on tumor suppression and negative effects on aging
related processes [164]. The transcription factor and tumor
suppressor p53 are involved in DNA repair and cellular stress
response, as well as cellular cycle control. In addition, p53
modulates both the cell senescence and the aging process,
through the coordination of specific cellular pathways [165,
166]. It is not clear whether p53 mechanisms in cell senes-
cence and aging are common [160]. An increased senescence
secretoma causes detrimental effects over the years and
contributes to the typical disruption of aged tissues [8, 167,
168]. Senescent cells endowed with the semiselective marker
of senescence p16 drive age-related pathologies, which are
delayed or prevented by the selective elimination of the
senescent cells [169]. A partial list of suggested markers of
cell senescence in human tissues, both aged and affected
by age-related pathologies, is reported in Table 2 [170–197].
Lungs show a typical example of cell senescence associated
with the progressive, age-related organ dysfunction. The OS
generated by the potent cigarette oxidants is a key element
in the pathogenesis of the pulmonary emphysema, induced
by the chronic smoking.The fibroblasts that provide essential
support and matrix for lung integrity show reduced prolifer-
ation rate and increased SA-𝛽gal activity in patients affected
by pulmonary emphysema. These senescent fibroblasts con-
tribute to the lung disease by affecting the tissue homeostasis.
Also, senescent features of the endothelial cells in chronic
smokers associate with premature vessels atherosclerosis. In
patients with severe coronary artery disease, OS accelerates
the senescence of endothelial cells, which is related to risk
factors for cardiovascular disease [198]. A further example
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Table 2: Clinical examples of senescence-associated biomarkers detected in organs and tissues of patients affected by age-related diseases.
Organ/tissue Senescence-associated biomarkers Clinical references
Cardiovascular diseases
Aged vascular tissues Telomeres length, SA-𝛽Gal, p16, and p21 [170, 171]
Atherosclerosis
Systolic heart failure
Malignant tumors
Lung cancer Telomeres length, SA-𝛽gal [172, 173]
Breast cancer SA-𝛽gal, p21, p16, DEP1, NTAL, EBP50, STX4, VAMP3,ARMX3, B2MG, LANCL1, VPS26A, and PLD3 [174, 175]
Neuroblastoma SA-𝛽gal [176]
Astrocytoma SA-𝛽gal [177]
Mesothelioma SA-𝛽gal, p21 [178]
Melanoma SA-𝛽gal, p16, and p21 [179]
Prostate cancer SA-𝛽gal, Glb1, and HP1g [154, 180]
Liver cancer Telomeres length, SA-𝛽gal [181]
Colorectal cancer Short telomeres [182]
Fibrosis
Idiopathic pulmonary fibrosis Telomeres length, IGFBP5, and SA-𝛽gal [183, 184]
Cystic fibrosis Telomere length, p16 [185]
Liver fibrosis Telomere length, IGFBP-5, SA-𝛽-gal, and p21 [183, 186]
Renal fibrosis p16 [187, 188]
Neurological disorders
Alzheimer’s disease SA-𝛽-gal [189, 190]
Other diseases
Chronic obstructive pulmonary disease Telomere length, p16, p21, and SA-𝛽gal [191, 192]
Pulmonary hypertension p16, p21 [192, 193]
Emphysema Telomere length, IGFBP-3, IGFBP-rP1, p16INK4a, and p21 [194, 195]
Benign prostatic hyperplasia SA-𝛽gal [196, 197]
of aging dysfunction related to cell senescence is shown by
the scaffolding protein Caveolin 1 (Cav1), which controls
molecular signaling in caveolar membranes. Cav1 promotes
cellular senescence in age-related pathologies, by mediating
p53 activation with EGF modulation, focal adhesion, and
small Rho GTPase-dependent signaling. The upregulation
of the Cav1 promoter by high ROS levels contributes to
explaining how OS promotes cell senescence effects in aging
and age-related diseases [198]. In addition, the interplay
between different conditions of mitochondrial homeostasis
and ROS-dependent signaling pathways contributes to aging
process, through the cell senescence induction and stabi-
lization [199]. Yet ROS-independent signaling pathways link
dysfunctions in mitochondria and aging, through the cell
senescence process [6, 151]. As a new approach, preclinical
and clinical studies demonstrate the therapeutic effects of
the aging inhibitor rapamycin, whose signaling pathway is
involved in cellular senescence [160, 200].
In conclusion, cell senescence reduces the age-related
tumor development and contributes to human aging, sug-
gesting that aging might be switched for tumorigenesis [201,
202]. ROS may modulate tumor suppression process, which
is induced by the senescence, thus participating in anticancer
mechanisms, although ROS may act as tumor promoters in
definite conditions [48]. With the cell senescence and aging
controlled by cells and cellular environment, the possibility
is suggested that the two processes may be subjected to
interventional therapies [203, 204].
5.2. Epigenetic Mechanism in Cell Senescence (ROS Involve-
ment). The epigenetic control of acute and chronic cellular
senescence allows for the two processes that are involved in
various conditions that lead to the cells longevity preventing
cell death and tumorigenesis [205]. The abrogation of tumor
suppressor pathways, as p53 and p16/Rb, bypasses the cell
senescence, thus leading to the tumorigenic phenotypes
acquiring [206]. The mechanisms that balance the tran-
scriptional state of the chromatin are not fully understood.
Some regulative changes involve the histone proteins that
coordinate the DNA accessibility, through transcription fac-
tors, besides the DNA replication and repair. The Polycomb
Repressor Complex 2 (PRC2) initiates and preserves specific
histone methylations, thus acting as an epigenetic mark that
mediates targeted genes [207]. The repression of the histone
activity by the Polycomb Group (PcG) proteins causes gene
silencing, but it can be countered by specific demethylases,
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which erases the methyl mark [208]. The upregulation of
many PRC target genes leads to global epigenetic changes
[209–211]. Specific transcription factors [212], as well as
long noncoding RNAs [213], are involved in the recruitment
performed by PRC. PRC2 takes a crucial part in silencing the
locus of p16, the marker that is upregulated during cell senes-
cence [212]. The reversal of chromatin epigenetic pattern via
deacetylation, demethylation, and dephosphorylation is sig-
nificantly involved in underscoring both flexible anddynamic
nature of histone modifications [214]. The histone demethy-
lases JMJD3 produce diverse outputs of biological function,
depending on the action of their transcriptional complexes.
Different expression of these demethylases, which have
tumor suppressor activities during the “stress-induced senes-
cence” [215, 216], is reflected into cellular phenotype changes
and variations associated with cellular senescence [217]. The
JMJD3 gene is located near the p53 tumor suppressor gene,
that is, a genomic area that is frequently lost in variousmalig-
nancies. The SIRT1 histone deacetylase (SIRT1) is a known
regulator of age-related diseases that regulates the senescence
secretoma components, by silencing their promoter regions
epigenetically. SIRT1 plays a pivotal role in stress modulation
also through p53 deacetylation, acting against aging and age-
related diseases. As indicated above, the high ROS levels
activate p53, which, in turn, activates p53-mediated apoptosis
and cell senescence. Moreover, SIRT1 regulates the ROS-
dependent FOXO factors, which are responsible for cell
growth, proliferation, and longevity. The characteristic ROS
increase during aging may be responsible for the decreased
SIRT1 activity, which facilitates the senescent-like phenotype.
SIRT1 causes oxidant effects, as well as antioxidant effects, by
acting on epigeneticmodifications, which include acetylation
and deacetylation (see references in [128, 146]). Experiments
on cell senescence induction show different molecular mech-
anisms in acute versus chronic senescent cells. A better
knowledge of the order in which epigenetics mechanisms
change during the cell senescence progression, from initial
towards full senescence, is believed to be vital for finding
therapies against age-related disorders [9].
5.2.1. Noncoding RNA. Latest genomics tools and sequenc-
ing approaches have helped unravel large chromosomes
stretches, which were previously deemed not transcribed
[218, 219]. These sequence regions contain noncoding RNA
(ncRNA), which is known as long lncRNAs, and short
ncRNAs. Among short ncRNAs, the microRNAs (miRNAs)
have emerged as being able to control the gene expression,
either by blocking targeted mRNA translation or by mRNA
degrading [220, 221]. Recently, ncRNA role is gaining more
importance in age-associated dysfunctions as cardiovascu-
lar diseases [222, 223]. The senescence-associated lncRNAs
are differentially expressed in proliferating and senescent
fibroblasts, as assessed by RNA sequencing [224–226]. Tox-
icological studies associate increased ROS production with
increased expression of a set of 115 lncRNAs, which signifi-
cantly affect p53 signaling pathway [227]. A mitochondrial-
transcribed lncRNA is induced in aorta and endothelial cells
aging, during the “replicative vascular senescence,” which is
partly responsible for age-associated cardiovascular diseases,
but not in the “stress-induced premature senescence” by ROS
[228].
5.2.2. microRNA (miRNA, miR). Normal cellular develop-
ment and homeostasis are under the control of miRNAs,
throughout the entire life [229], since miRNAs regulate
the gene expression in biological processes as proliferation,
development, differentiation, and apoptosis. Yet several miR-
NAs families control cell senescence at multiple levels, by
regulating the autophagy process and the gene expression
involved in ATP and ROS production. Some miRNAs may
induce ROS production that generates a self-sustaining ROS
vicious cycle [159]. miRNAs constitute a connection between
aging, cell senescence, and cancer. The miRNAs dysregula-
tion causes the activation of pathways they normally repress.
The event may activate aberrant pathways and also aging
mechanism in young individuals [222]. Although current
studies are monitoring miRNA tissues and systemic alter-
ations, instead of miRNA changes through lifespan and
metabolic modifications, several profiles of miRNA expres-
sion demonstrate changes during the aging. As an example,
miR-29, which targets the genes of type IV collagen and
maintains the structure of the extracellular matrix, increases
in elderly mice, thus causing collagen decreasing, a tissues
basement membranes weakening [230]. Only few miRNAs
have been directly linked to age-related changes in cellular
and organ functions, whereas many miRNAs have been
directly connected with disease states. It is unclear if the
modifications of miRNA profiles are mostly involved in
pathological changes onset or if they mark the senescence
end, which leads to the organ aging and dysfunction. Altered
expression in miRNA activity has been observed in elderly
people, as in the case of miR-34a, which belongs to a family
with conserved functions in controlling aging and age-related
diseases [203, 231, 232]. miR-34a targets ROS scavenger
enzymes inducing OS [159]. The miR-34a upregulation or
overexpression has been associated with cell proliferation
inhibition, subsequent cell senescence induction, and pre-
mature death, in both endothelial progenitor and mature
cells. miR-34a causes memory function impairment when it
is upregulated in aged mice and in models for Alzheimer’s
disease (AD), while miR-34a targeting restores the memory
function [233]. Also, the miR-34 mutation of the loss-
of-function delays the age-related decline markedly, thus
resulting in extended lifespan and increased resistance to the
heat and the OS. The human miR-34a is downregulated in
Parkinson’s disease brain, while it is upregulated in AD brains
[234] and in plasma of Huntington’s disease patients [235].
Several miRNA families are modulated by ROS in
the development of mitochondria-mediated cell senescence,
which are, indirectly or directly, implicated in human
pathologies. Little is known about the roles of ROS-
modulated miRNAs in cell function. The molecular mecha-
nisms that control neuronal response to OS have been deeply
studied in different strains of senescence accelerated mice,
based on the consideration that OS plays a critical role in AD
etiology and pathogenesis. OS upregulates a group of miR-
NAs (miR-329, miR-193b, miR-20a, miR-296, andmiR-130b),
which is associated with affecting 83 target genes. Among the
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genes, mitogen-activated protein kinase signaling pathway
has been suggested to play a role in pathogenesis of neurode-
generative diseases [233]. OS effects on vascular homeostasis,
including angiogenesis in physiological processes and age-
related diseases, are largely studied in human umbilical
vein endothelial cells (HUVECs), considering that miRNAs
modulate endothelial cells response to OS. ROS induce the
expression of miR-200 family members (miR-200c, miR-
141, miR-200a, miR-200b, and miR-429), which determines
apoptosis and cell senescence both in HUVEC cells and in
a model of hind limb ischemia, which shows OS-mediated
mechanism [236]. The miR-200 family plays a causative role
in the vascular diabetic inflammatory phenotype in a diabetic
model and in the human vasculopathy disease, suggesting
that miR-200 inhibition might represent a therapeutic target
to prevent OS negative effects on cell function and survival
[146]. Also, miR-200 family has been extensively studied in
epithelial-to-mesenchymal transition of cancer cells [236].
Lately, miR-760 and miR-186 upregulation has been asso-
ciated with replicative senescence in human lung fibroblast
cells.These miRNAs cooperate to induce senescence through
the ROS-p53-p21Cip1/WAF1 pathway, which depends on the
ROS generated by the downregulation of the protein kinase
2 (CK2𝛼). A better understanding of the mechanisms of CK2
regulation might provide new therapeutic options to restore
the function of lungs in aged people. An example of the
increasing evidence thatmiRNAs are critically involved in the
posttranscriptional regulation of cell functions, including the
ROS signaling modulation, is underlined in Figure 2.
6. Conclusion and Future Perspectives
The multifactorial and inexorable phenomenon of aging
worsens the human functions at multiple levels, causing a
gradual reduced ability to resist stress, damage, and illness.
Healthy aging appears to be an ideal healthcare priority that
entails a better understanding of aging, with the aim of
slowing down the process and preventing or even treating
its related pathologies [200]. Indeed, genetic insights com-
bined with findings from animal and cellular models have
advanced our understanding of pathways that lead to age-
related features, highlighting possible interventional targets
[2–5]. The cellular senescence process is considered an aging
hallmark, because it drives the cells through longevity, by
hampering tumorigenesis and cell death, and is involved in
many age-related diseases [97, 205, 206]. The cell senescence
is a feature that characterizes somatic cells, except for most
tumor cells and certain stem cells [6–10]. The senescent cells
produce a specific secretoma that cause beneficial effects,
through its autocrine and paracrine mechanisms. When the
senescent cell program is inefficiently developed, as it occurs
during the aging, the secretoma causes detrimental effects
[151–153, 167, 168, 199]. In the recent years, evidence has been
accumulating that ROS, which include H
2
O
2
, superoxide,
anion, and hydroxyl radicals, generated from both intrinsic
and extrinsic events, inhibit cell growth and induce cell death
and senescence in a context-dependent manner [157, 236].
Through the understanding of the ROS role as signaling
molecules in a myriad of signaling pathways, ROS levels are
no longer considered as mere metabolic byproducts but are
believed to be a “redox biology” that regulates physiological
functions, including signal transduction, gene expression,
and proliferation [37]. Firstly, it has been evidenced that the
DNA damage caused by ROS acting as mutating agents con-
tributes to the induction and maintenance of the cell senes-
cence process [9, 156]. More recently, particular attention has
been focused on the ROS involvement as signaling molecules
in cell senescence induction, without causing DNA damage.
Signaling pathways via Ras, p53, p21, and p16 have been
defined to generate ROS, which may act as tightly regulated
process contributing to the cell senescence induction [20, 157,
158]. Cause-effect relationships between cell ROS production
and cell senescence have been investigated through diverse
pathways that include the field of mitochondrial DNA and
autophagy inhibition and the effects of the microRNAs miR-
210 and miR-494 in various mitochondrial processes [159].
These pathways highlight ROS contribution to prime cell
senescence at diverse levels, among which epigenetic level
is attracting more and more attention in studies aimed at
the senescence control [227, 233, 236]. Indeed, the epigenetic
modulation provides the essential and flexible interface
between the organisms and the environment, which results
in being essential for all the cell functions [122, 123, 129],
throughout the lifespan [135–137]. A major breakthrough in
the last decades has been the understanding that epigenetics
contribute to human diseases development.
In parallel, the “OS theory of aging” remains the most
documented mechanistic hypothesis of aging, although it
does not necessarily imply ROS imbalance as the earliest
trigger or the main cause of aging [98–103]. Therapeutic
ROS modulation is suggested as relevant in aging and related
events [95, 96, 114]. Also, the senescent cells have been
identified as a novel potential therapeutic target in the aging
and age-related diseases [169, 171]. Further research is needed
to define when and where cell senescence results in being
favorable or unfavorable to organismal health. Both pro-
and antisenescent therapies can be equally helpful, when
they are opportunely modulated and balanced. Prosenescent
therapies contribute to minimize damage in the cancer
disease and in the active tissue repair by limiting proliferation
and fibrosis, respectively, while antisenescent therapies may
help to eliminate accumulated senescent cells and to recover
tissue function. The current research points to a double
objective: to define the changes about the redox-sensitive cell
pathways and to define the OS role in linking environmental
factors with epigenetic modifications.
Particular emphasis is addressed to novel mechanism of
ROS and epigenetics in cell senescence and aging [160, 165,
166]. The histone demethylases network is often synergizing
with the action of histone deacetylases, histone methyl
transferases, and various nuclear transcriptional complexes,
thus ensuring that the chromatinic environment is correct
for the cell [128, 146]. Preclinical and clinical examples
of ROS-dependent epigenetic modifications [125–127, 130–
134, 138] extend their effects to aging [135, 136] and age-
related diseases [137, 142–144, 146–149], particularly towards
cancer disease [139–141, 145]. Among the noncoding RNAs,
miRNAs families provide a broad silencing activity of mRNA
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p53
DNA damage
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Figure 2: ROS-mediated senescence. Besides causing DNA damage and mitochondria dysfunction, OS activates p53 that, in turn, induces
prooxidant genes and imbalances antioxidant genes induction. The set of alterations caused by ROS lead to induction of cell senescence,
which, in turn, can develop both positive and negative effects; miR34a expression increases with aging in many tissues downregulating SIRT1
protein activity (a longevity promoting factor) and PNUT protein (a DNA protecting factor which prevents telomere attrition and is involved
in tissues repairs).
targets, in a sequence dependent fashion that modulates
the stress response [159]. Accumulating evidences show that
stressors, including ROS, potentially alter the function of
miRNA-processing in aging organisms, which renders the
cells even more prone to stress, linking aging and cancer.
Several miRNAs families induce ROS level increase in aging
or target factors involved in the ROS signaling. In addition,
ROS increase highly correlates with a specific miRNA dys-
regulation, which mediates the cross talk between p53, NF-
𝜅B p65, and ROS. All these events have been associated with
cell senescence [203, 231, 232]. At the same time, certainly
several miRNAs families are modulated by ROS in the devel-
opment of mitochondria-mediated cell senescence, which
are, indirectly or directly, implicated in human pathologies
[159, 233, 236]. Because epigenome is so tightly regulated and
complex, understanding individual modifications and their
network of interaction offers the potential to design drugs
that are very effective therapies against a number of diseases
[124, 203–205, 219–222]. More reliable OS biomarkers, as well
as OS related epigenetic mechanisms, have emerged over the
last years as potentially useful tools to design therapeutic
approaches aimed at modulating in vivo enhanced OS.
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